Skip to main content
. 2019 Dec;8(6):854–861. doi: 10.21037/tlcr.2019.11.06

Figure 1.

Figure 1

Percentage responders of non-small cell lung cancer patients stratified for their given treatment [chemotherapy or tyrosine kinase inhibitors (TKI)] and circulating tumor cell (CTC) presence at baseline.